Case Report: Pulmonary sarcomatoid carcinoma complicating TP53 mutation treated successfully with Tislelizumab combined with Anlotinib—a case report

Case Report: Pulmonary sarcomatoid carcinoma complicating TP53 mutation treated successfully with Tislelizumab combined with Anlotinib—a case report

Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of lung malignant tumor. Conventional chemotherapy has a suboptimal effectiveness. PSC has the characteristics of rapid disease progression and poor prognosis. We herein report a 56-year-old male patient with substantial smoking history was pat...

Full description

Bibliographic Details
Main Authors: Yu-Feng Li, Xin-Fei Zhao, Yue Tian, Xin-Yao Xiao, Cai-Yun Yan, Hua Shen
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Genetics
Subjects:
Tislelizumab
Anlotinib
pulmonary sarcomatoid carcinoma
TP53 mutation
hepatitis C
case report
Online Access:https://www.frontiersin.org/articles/10.3389/fgene.2022.949989/full

Internet

https://www.frontiersin.org/articles/10.3389/fgene.2022.949989/full

Similar Items